Main Content
About Us
GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
our mission
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
Our Objectives
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
We hope you will cheer on @MichaelMay5 when he receives the 2023 Le Prix Luc Sensebé Innovation and Leadership Award at @ISCTglobal's welcome address and major awards presentation on May 31 in Paris. Congratulations to all the award recipients: https://www.isctglobal.org/isct2023/program
GAiT joins CCRM on their latest podcast to discuss the clinical potential of induced Pluripotent Stem Cells
Commercializing Living Therapies with CCRM: Unlocking the potential of induced pluripotent stem...
Show Commercializing Living Therapies with CCRM, Ep Unlocking the potential of induced pluripotent stem cells - Dec 14, 2022
podcasts.apple.com
With a very heavy heart, we announce the passing of our CEO and co-founder, Susan Solomon, following a long battle with ovarian cancer. We owe all that NYSCF has accomplished to Susan, and no words can express our gratitude and awe for her catalytic impact on stem cell research.
Great panel on regulatory futures for CGT from various perspectives - Niloofar Davoodi, @TakedaPharma, Ian Rees, @MHRAgovuk, Michael von Forstner, @biogen and led by Jacqueline Barry, @CGTCatapult
#advancedtherapieseurope #ate2022 #ate22 #celltherapy #regulatory
Companies developing iPSC-based cell therapies
Characterization of advanced therapies: leveraging advanced #analytics to avoid #FDA holds
Find out the key #assay types needed for successful characterization of #cellandgenetherapy
Read the FastFacts poster, or watch the video, here: http://bit.ly/3AxQmMz
#celltherapy